Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.58 |
| ▸ | RAF1 | P04049 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536884 | 1.00 | BRAF (0.58) | BRAFRAF1MEN1HTTRAB9A | |
| SCHEMBL4016155 | 0.92 | RAF1 (0.58) | BRAFRAF1MEN1HTTRAB9A | |
| SCHEMBL5489272 | 0.89 | MEN1 (0.55) | BRAFRAF1MEN1HTTRAB9A | |
| SCHEMBL22915771 | 0.87 | MEN1 (0.54) | MEN1HTTRAB9AKMT2ALCK | |
| SCHEMBL18988941 | 0.85 | BRAF (0.50) | BRAFRAF1LCKKITMAPK14 | |
| SCHEMBL19529425 | 0.85 | BRAF (0.54) | BRAFRAF1MEN1HTTRAB9A | |
| SCHEMBL16035530 | 0.85 | KCNQ3 (0.55) | BRAFRAF1MEN1HTTRAB9A | |
| SCHEMBL29427247 | 0.85 | KCNQ3 (0.55) | BRAFRAF1MEN1HTTRAB9A | |
| SCHEMBL25272009 | 0.84 | LMNA (0.61) | BRAFMEN1HTTRAB9AKMT2A | |
| SCHEMBL13197996 | 0.84 | NPC1 (0.57) | MEN1RAB9AKMT2AKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2021254464-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| CN-108699065-B | Tricyclic compounds and compositions as kinase inhibitors | 诺华股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| EP-3390404-B1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3191467-B1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | NOVARTIS AG | 2009-12-10 | — | — | US | disclosed |
| EP-2043638-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008821-A2 | USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | BRAF 21/4885RAF1 115/4885MEN1 1392/4885 |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | MAP3K1, MAP3K20, MAP3K2 | BRAF 6/4885RAF1 28/4885MEN1 1933/4885 |
| US-20090306083-A1 | Use of Trifluoromethyl Substituted Benzamides in teh Treatment of Neurological Disorders | EPHB3, EPHB2, EPHB1 | BRAF 286/4885RAF1 1045/4885MEN1 4676/4885 |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | ABL1, ERBB2, EPHB2 | BRAF 6/4885RAF1 32/4885MEN1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.